HMBD-002 represents a unique first-in-class anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development.


The targeting of immune checkpoints is a promising approach for the treatment of cancer. Although programmed cell death protein 1 (PD-1) blockade therapy has been approved for several types of cancers, approximately half of the patients treated with immune-checkpoint inhibitors do not benefit from these therapies. VISTA (V-domain immunoglobulin suppressor of T cell activation) is a co-inhibitory immune checkpoint that potently suppresses T cell activity in a variety of cancers and has been associated with a lack of response to other checkpoint therapies.

Engineer with Precision

HMBD-002 was engineered to bind to VISTA at a specific site that was predicted to be essential for ligand-binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA expressing cells that play many important roles in the immune system.

Preclinical models have shown that HMBD-002 as a monotherapy inhibits tumor growth and significantly prolongs progression-free survival, with no observed toxicity. It has also shown synergy when used in combination with anti-PD-1 therapy.

HMBD-002 Binds To Key Functional Interface Inhibiting Tumor Growth

Develop with Precision

HMBD-002 is being developed for multiple cancers that have strong evidence of VISTA mediated suppression, both as a monotherapy and in combination with PD-1 inhibitor. The Cancer Prevention and Research Institute of Texas (CPRIT) awarded Hummingbird Bioscience a US$13.1 million product development grant to support the development of the anti-VISTA therapeutic antibody.

HMBD-002 is currently in clinical trials: NCT05082610

Publications & Posters

Related News